!" CORPORATE FACT SHEET NBD is supercomputing biotech company that uses proprietary structure based technologies to redesign the pipeline of pharma companies dedicated to the development of novel drugs. NBD advantages may allow an acceleration of up to two years in the stages of drug development besides a cost reduction of 15-20%, saving an estimated average of 40 M . NBD business model will alternate high and moderate risk to maximize the return success for its stakeholders by generating its own drug discovery projects and offering cutting-edge services, respectively. The competitive advantages of NBD are its proprietary technologies (software platforms and chemical libraries), supercomputing power, and experience and excellence of its team, which has a long track record of constant, meticulous, highly specialized work at the forefront of science. These three pillars allow NBD to offer a service that few companies are able to provide. Additionally, NBD will develop further tools to expand its knowledge to genomics and precision medicine. MareNostrum Supercomputer , 48896 cores dedicated to solve the most challenging scientific projects. NBD featured services: Chemoinformatics, Ligand-based & Structure-based molecular design and OMICS-based discovery. Products: PELE for predicting the dynamic interactions between proteins and ligands applied to drug design. ED/MD: method to explore the flexibility of macromolecular targets. MDWeb: A set of programs that facilitates rapid workflows to automate molecular dynamics calculations enabling the generation of large MD libraries such as MoDEL, which holds simulations of more than 1700 proteins. ChemistriX: a combichem database of novel, IP-liability free lead- like molecules generated by an expert panel of medicinal chemists to complement the currently available catalogues. ALL RIGHTS RESERVED © NBD I NOSTRUM BIODISCOVERY 2016 Target Market: Structure-based drug design segment, which is expected to reach 4.285,1 M$ by 2020 growing at a CAGR of 21%. Its large share is attributed to the growing research investments for development of drug discovery, disease modeling technologies and innovations in computational methods. Target Customers: Big Pharmas, Small/Medium Pharmas and CROs. Oriol Nicolás, PhD (CEO) Robert Soliva, PhD (CSO) Oriol Pla (CFO) Founded in 2015 1 Patent & 1 Copyrighted software 0,5M seed capital Private Company Modesto Orozco, PhD (President) Victor Guallar, PhD (SAB Head) Fundación Marcelino Botín Barcelona Supercomputing Center IRB Barcelona ICREA Fundació Bosch i Gimpera STRATEGIC ADVISORY BOARD Emilio Díez, PhD former Vicepresident, GSK Joan Albertí, PhD former DMPK head, Almirall Jonathan Essex PI University of Southampton Juan Fernández-Recio PI BSC NBD | Nostrum Biodiscovery C/ Jordi Girona 29 Nexus II Building 08034 Barcelona [email protected] www.nostrumbiodiscovery.com AT A GLANCE EXECUTIVE OFFICERS STAKEHOLDERS CONTACT